FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.778,41 -1.564,57 (-2,59%)
Kyowa Kirin Co., Ltd. (KYKOF)
| Chiusura precedente | 17,63 |
| Aperto | 17,63 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 17,63 - 17,63 |
| Intervallo di 52 settimane | 15,78 - 22,67 |
| Volume | |
| Media Volume | 465 |
| Capitalizzazione | 9,478B |
| Beta (5 anni mensile) | 0,20 |
| Rapporto PE (ttm) | 25,19 |
| EPS (ttm) | 0,70 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | 0,39 (2,23%) |
| Data ex dividendo | 27 giu 2024 |
| Stima target 1A | N/D |
GlobeNewswireKyowa Kirin to Acquire Orchard Therapeutics
-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a t
GlobeNewswireTenapanor for Hyperphosphatemia Approved in Japan
Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty Partners under a Financing Agreement WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced
